News

Video

Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

Author(s):

Aditya Bardia, MD

Aditya Bardia, MD, presents key data from biomarker and subgroup analyses of the EMERALD trial.

Related Videos
Arya Mariam Roy, MBBS
A Phase 0/1 ‘trigger’ trial of BDTX-1535 in recurrent high-grade glioma (HGG) patients with EGFR alterations or fusions
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
VK Gadi, MD, PhD
Ana Christina Garrido-Castro, MD
Julia Foldi, MD, PhD
Kevin Kalinsky, MD, MS
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Related Content
Karthik V. Giridhar, MD
June 12th 2024

Decreases in ctDNA VAF Tied to Improved CBR With Imlunestrant in Pretreated ER+/HER2– Advanced Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Erin Frances Cobain, MD
June 8th 2024

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Shengfeng Li
June 3rd 2024

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion

Giuseppe Curigliano, MD, PhD
June 2nd 2024

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer